Announcements Trials
Browse Landscape

Phase

Phase NA 10Phase 3 9Phase 2 9Phase 1/2 7Phase 1 6Phase 2/3 1

Status

Completed 3Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 13INDUSTRY 6NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 3Thoracic 1Lymphoid 1Dermatologic 1

Conditions

Neoplasms 1522Carcinoma, Non-Small-Cell Lung 758Breast Neoplasms 572Neoplasm Metastasis 531Colorectal Neoplasms 448Melanoma 391Leukemia, Myeloid, Acute 372Multiple Myeloma 364Ovarian Neoplasms 354Recurrence 336Lymphoma 334Advanced Solid Tumors 325Lymphoma, Non-Hodgkin 315Prostatic Neoplasms 300Pancreatic Neoplasms 285Advanced Solid Tumor 240Stomach Neoplasms 233Carcinoma, Renal Cell 226Squamous Cell Carcinoma of Head and Neck 211Lung Neoplasms 210Solid Tumor 204Leukemia, Lymphocytic, Chronic, B-Cell 198Triple Negative Breast Neoplasms 185Solid Tumors 183Carcinoma, Hepatocellular 165Hematologic Neoplasms 155Head and Neck Neoplasms 153Lymphoma, Large B-Cell, Diffuse 148Lymphoma, Follicular 146Glioblastoma 145

Interventions

Dexamethasone 2ricolinostat 1pomalidomide 1daratumumab 1Lenalidomide 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Disease × Clear all
NCT07075185 2026-04-24

inMMyCAR

Kelonia Therapeutics, Inc.

Phase 1 Recruiting
70 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT06403436 2026-04-13

TT-CSP-001

TOLREMO therapeutics AG

Phase 1 Active not recruiting
50 enrolled

Disease, Neoplasms

NCT04855929 2024-11-08

ANV419-001

Anaveon AG

Phase 1 Completed
55 enrolled
Thoracic

Disease, Lung Neoplasms, Neoplasms, Recurrence

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Anaveon AG

Phase 1 Terminated
4 enrolled
Plasma cell

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT04904120 2023-11-07

TIMAR1

Perspective Therapeutics

Phase 1 Completed
7 enrolled
Dermatologic

Uveal Melanoma, Disease, Melanoma, Neoplasm Metastasis, Neoplasms

NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1 Completed
16 enrolled
Plasma cell

Disease, Multiple Myeloma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡